Analysis:

## (a) Source Analysis

**Source 1 (Nasdaq Earnings):** Unusable - contains only website navigation elements with no substantive data.

**Source 2 (Business Insider Markets):** High-quality financial data source. Key factual information:
- Recent analyst ratings (Jan 22, 2026: Barclays $262 target, Buy; Jan 7, 2026: Wells Fargo downgrade to Hold, $235 target)
- 2026 consensus estimates: Revenue $18,239M, EPS $23.43, P/E 8.59
- 17 analysts covering with average price target implied around $235-262 range
- Historical 2024 data: 10.82% revenue growth, 59.17% income growth

**Source 3 (Market Chameleon):** Unusable - error page only.

**Source 4 (Quiver Quant Insider Trading):** Factual data on insider activity:
- Recent insider sales (Nov 2025): 4 sales, 0 purchases over 6 months
- Institutional activity mixed: 321 added shares, 328 decreased positions
- Analyst consensus: 4 buy ratings, 0 sell ratings; median price target $240, range $219-$302

**Source 5 (Ad-hoc-news, Jan 2, 2026):** Mixed quality - appears promotional but contains verifiable claims:
- Factual: 5-day gain ~3-4%, 90-day double-digit gain, 1-year gain ~18-20%
- Price levels: mid-$170s to low $180s range at time of writing (early January 2026)
- Opinion (analyst consensus): Most ratings Buy/Overweight, targets "high $180s to low $200s"
- Business fundamentals: easing staffing pressures, robust behavioral health volumes (cannot verify independently)

**Source 6 (Simply Wall St, Jan 29, 2026):** Analysis site with proprietary methodology:
- Factual: Last close $201.26 (Feb 1, 2026), 8.9% 1-year return
- DCF intrinsic value $569.94 (proprietary model - should be treated as opinion)
- P/E ratio 9.22x vs industry 21.99x (factual comparison)

**Agent Report:** Provides critical methodology for historical analysis:
- Identifies Stooq as free source for daily historical prices since 2010
- Lists macro events Feb 2-14, 2026: ISM PMI (Feb 2), JOLTS (Feb 3), ADP (Feb 4), ISM Services (Feb 4), Jobs Report (Feb 6), CPI (Feb 11)
- No UHS corporate events scheduled in forecast window
- Notes inability to actually calculate historical Feb 2 + 10 trading day patterns without downloading data

## (b) Reference Class Analysis

**Possible Reference Classes:**

1. **UHS 10-trading-day returns following February 2nd specifically (2010-2025):** Most specific but requires data not provided. Would show seasonal/calendar patterns unique to this date.

2. **UHS 10-trading-day returns across all periods (2010-present):** Broader sample showing general short-term volatility. More data points but loses date-specific patterns.

3. **Healthcare stocks 10-trading-day returns during macro event windows:** Captures sector behavior during high-information periods (employment, CPI data).

4. **UHS returns during recent uptrend continuation:** The stock appears to be in an uptrend (18-20% 1-year gain, trading near $201-203 as of late Jan/early Feb 2026).

**Selected Reference Class:** UHS 10-trading-day returns across all periods, with adjustment for current momentum and macro event risk. This balances sample size with relevance, though the lack of actual historical data is a significant limitation.

## (c) Timeframe Analysis

**Prediction Timeframe:** 10 trading days (Feb 2, 2026 to Feb 14, 2026 - approximately 8 calendar days)

**Key Timeframe Characteristics:**

1. **Very short horizon:** 10 trading days is essentially noise-dominated for fundamental investors. Technical factors and macro events dominate.

2. **Macro event density:** Unusually high concentration of Tier-1 releases:
   - Feb 6: Jobs Report (historically high-volatility event)
   - Feb 11: CPI (inflation data, market-moving)
   - Multiple other employment/economic indicators

3. **Recent momentum:** Stock gained 3-4% in 5 days prior to question opening (late Jan), suggesting short-term bullish momentum but also potential for mean reversion.

4. **Starting point context:** Opening price on Feb 2, 2026 likely around $201-203 based on Feb 1 close of $201.26. Question asks if Feb 14 close will be higher.

**Historical Pattern Expectations (without specific data):**

For a typical stock with ~20-30% annualized volatility:
- 10-day standard deviation â‰ˆ 3-4%
- Random walk expectation: ~50% chance of positive return
- With slight positive drift (equity risk premium): ~52-53% base rate

**Momentum considerations:**
- Recent 5-day gain suggests short-term overbought potential
- 90-day strong performance could indicate trend continuation
- But 10 days too short for momentum strategies to reliably persist

## (d) Justification

**Factors Supporting Higher Price on Feb 14:**

1. **Strong institutional support:** 321 institutions added shares vs 328 reduced (nearly balanced), with major additions from PZENA (+310%), Price T Rowe (+386%)
2. **Analyst consensus bullish:** 4 buy/0 sell ratings, price targets $219-$302 (median $240) well above ~$201 starting point
3. **Recent momentum:** 18-20% 1-year gain, double-digit 90-day gain
4. **Valuation support:** P/E 9.22x vs industry 21.99x suggests undervaluation
5. **Positive drift:** Equities have inherent upward bias over time

**Factors Supporting Lower Price on Feb 14:**

1. **Mean reversion risk:** Recent 3-4% 5-day gain may reverse
2. **Macro event risk:** Jobs Report (Feb 6) and CPI (Feb 11) create two-sided volatility risk. Bad news could trigger 2-5% drops
3. **Insider selling:** 4 sales, 0 purchases in past 6 months signals potential caution
4. **Short timeframe randomness:** 10 days insufficient for fundamental thesis to play out
5. **Mixed recent analyst actions:** Wells Fargo downgrade to Hold (Jan 7), BofA downgrade to Sell (July 2025) show divergence

**Critical Unknowns:**
- Actual historical Feb 2 + 10 day performance
- Precise Feb 2, 2026 opening/closing price
- Market regime (risk-on vs risk-off) entering the period

**Integration:**

The 10-trading-day horizon is too short for fundamental analysis to dominate. The question essentially asks about short-term price direction in a macro-event-heavy period. 

Base rate for any stock over 10 days: ~50-53% (random walk with slight drift)

Adjustments:
- Recent momentum (+2-3%): Suggests near-term continuation but also mean reversion risk
- Macro event cluster (-2-3%): High volatility period increases tail risk on both sides
- Strong analyst support (+2-3%): Suggests institutional buying could support price
- Insider selling (-1-2%): Minor negative signal

Net adjustment: Approximately +0% to +2%, suggesting 52-55% probability range.

Outside view calibration:

Given the very short 10-trading-day timeframe, this forecast is essentially asking whether a stock will have a positive return over ~2 weeks. For any reasonably liquid stock, this approaches a coin flip with slight positive bias due to equity risk premium.

**Tethering to available data:**
- No specific historical Feb 2 + 10 day data available
- General equity return statistics suggest ~52-53% base rate for positive 10-day returns
- Recent momentum (3-4% in 5 days) is notable but could reverse
- Macro events (Jobs, CPI) create symmetric risk

**Probability calibration considerations:**

50% = Pure coin flip (no information)
52-53% = Equity risk premium baseline
55-58% = Modest momentum + analyst support
60%+ = Would require stronger trend evidence or lower volatility period

The combination of:
- Recent positive momentum (~3-4% in 5 days)
- Strong analyst consensus (4 buy/0 sell, targets $240+ vs ~$201 current)
- Institutional accumulation
- But offset by macro event risk and mean reversion potential

Suggests a probability modestly above the baseline but not dramatically so. The macro event cluster (especially Jobs on Feb 6 and CPI on Feb 11) introduces significant two-sided risk that prevents high confidence in either direction.

**Calibration check:** 
- 55% implies 11:9 odds - reasonable for "slight edge" scenarios
- 60% implies 3:2 odds - would need stronger momentum evidence
- 50% implies no edge - ignores available positive signals

Outside View Prediction:
56%